Skip to main content

Table 1 Response rates to anti-PD-1 and overall survival in NSCLC by study

From: PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?

Study Histology Treatment # patients ORR (%) Median response duration (months) OS (months)
Nivolumab
 Gettinger et al. [11]a All Nivolumab 3 mg/kg q2wks 37 24.3 17 14.9
Nivolumab 10 mg/kg q2wks 59 20.3 19.1 9.2
 Rizvi et al. [13] (CHECKMATE 063) Squamous Nivolumab 3 mg/kg q2wks 117 14.5 Not reached 8.2
 Brahmer et al. [14] (CHECKMATE 017) Squamous Nivolumab 3 mg/kg q2wks 135 20 Not reached 9.2
Docetaxel 75 mg/m2 q3wks 137 9 8.4 6
 Borghaei et al. [15] (CHECKMATE 057) Non-squamous Nivolumab 3 mg/kg q2wks 292 19 17.2 12.2
Docetaxel 75 mg/m2 q3wks 290 12 5.6 9.4
 Bauer et al. [55] All Nivolumab 3 mg/kg q 2wks 51 13.7 Not reported Not reported
Pembrolizumab
 Garon et al. [16] (KEYNOTE 001) All Pembrolizumab 2 mg/kg q3wks 6 33.3 12.5 9.3 (prior therapy)
Pembrolizumab 10 mg/kg q3wks 287 19.2
16.2 (no prior therapy)
Pembrolizumab 10 mg/kg q2wks 202 19.3
 Herbst et al. [17] (KEYNOTE 010) All Pembrolizumab 2 mg/kg q3wks 344 18 Not reached 10.4
Pembrolizumab 10 mg/kg q3wks 346 18.5 Not reached 12.7
Docetaxel 75 mg/m2 q3wks 343 9.3 6 8.5
  1. aCohorts receiving doses lower than 3 mg/kg were omitted from the table due to low response rates